These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36404995)

  • 1. Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study.
    Clark KEN; Csomor E; Campochiaro C; Galwey N; Nevin K; Morse MA; Teo YV; Freudenberg J; Ong VH; Derrett-Smith E; Wisniacki N; Flint SM; Denton CP
    Lancet Rheumatol; 2022 Jul; 4(7):e507-e516. PubMed ID: 36404995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing a candidate composite serum protein marker of skin severity in systemic sclerosis.
    Roblin E; Clark KEN; Beesley C; Ong VH; Denton CP
    Rheumatol Adv Pract; 2024; 8(2):rkae039. PubMed ID: 38645474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis.
    Farina G; Lafyatis D; Lemaire R; Lafyatis R
    Arthritis Rheum; 2010 Feb; 62(2):580-8. PubMed ID: 20112379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis.
    Clark KE; Lopez H; Abdi BA; Guerra SG; Shiwen X; Khan K; Etomi O; Martin GR; Abraham DJ; Denton CP; Stratton RJ
    Arthritis Res Ther; 2015 Mar; 17(1):73. PubMed ID: 25885360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Collagen Metabolites and the Enhanced Liver Fibrosis (ELF) Score as Fibrosis Markers in Systemic Sclerosis.
    Chen C; Wang L; Wu J; Lu M; Yang S; Ye W; Guan M; Liang M; Zou H
    Front Pharmacol; 2022; 13():805708. PubMed ID: 35177989
    [No Abstract]   [Full Text] [Related]  

  • 6. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.
    Maurer B; Graf N; Michel BA; Müller-Ladner U; Czirják L; Denton CP; Tyndall A; Metzig C; Lanius V; Khanna D; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1124-31. PubMed ID: 24981642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.
    Dobrota R; Maurer B; Graf N; Jordan S; Mihai C; Kowal-Bielecka O; Allanore Y; Distler O;
    Ann Rheum Dis; 2016 Oct; 75(10):1743-8. PubMed ID: 27016052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-frequency Ultrasound Assessment of Systemic Sclerosis Skin Involvement: Intraobserver Repeatability and Relationship With Clinician Assessment and Dermal Collagen Content.
    Flower VA; Barratt SL; Hart DJ; Mackenzie AB; Shipley JA; Ward SG; Pauling JD
    J Rheumatol; 2021 Jun; 48(6):867-876. PubMed ID: 33132218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.
    Wu W; Jordan S; Graf N; de Oliveira Pena J; Curram J; Allanore Y; Matucci-Cerinic M; Pope JE; Denton CP; Khanna D; Distler O;
    Ann Rheum Dis; 2019 May; 78(5):648-656. PubMed ID: 30852552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan.
    Kuwana M; Hasegawa M; Fukue R; Shirai Y; Ishikawa O; Endo H; Ogawa F; Goto D; Kawaguchi Y; Sato S; Ihn H; Takehara K
    Mod Rheumatol; 2021 Mar; 31(2):386-393. PubMed ID: 32552202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity.
    Lofgren S; Hinchcliff M; Carns M; Wood T; Aren K; Arroyo E; Cheung P; Kuo A; Valenzuela A; Haemel A; Wolters PJ; Gordon J; Spiera R; Assassi S; Boin F; Chung L; Fiorentino D; Utz PJ; Whitfield ML; Khatri P
    JCI Insight; 2016 Dec; 1(21):e89073. PubMed ID: 28018971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile.
    Skaug B; Khanna D; Swindell WR; Hinchcliff ME; Frech TM; Steen VD; Hant FN; Gordon JK; Shah AA; Zhu L; Zheng WJ; Browning JL; Barron AMS; Wu M; Visvanathan S; Baum P; Franks JM; Whitfield ML; Shanmugam VK; Domsic RT; Castelino FV; Bernstein EJ; Wareing N; Lyons MA; Ying J; Charles J; Mayes MD; Assassi S
    Ann Rheum Dis; 2020 Mar; 79(3):379-386. PubMed ID: 31767698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
    Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin.
    Rice LM; Mantero JC; Stifano G; Ziemek J; Simms RW; Gordon J; Domsic R; Lafyatis R
    J Invest Dermatol; 2017 Jan; 137(1):62-70. PubMed ID: 27640094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta.
    Farina G; Lemaire R; Pancari P; Bayle J; Widom RL; Lafyatis R
    Ann Rheum Dis; 2009 Mar; 68(3):435-41. PubMed ID: 18408251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
    Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
    Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis.
    Rice LM; Ziemek J; Stratton EA; McLaughlin SR; Padilla CM; Mathes AL; Christmann RB; Stifano G; Browning JL; Whitfield ML; Spiera RF; Gordon JK; Simms RW; Zhang Y; Lafyatis R
    Arthritis Rheumatol; 2015 Nov; 67(11):3004-15. PubMed ID: 26240058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subclinical dermal involvement is detectable by high frequency ultrasound even in patients with limited cutaneous systemic sclerosis.
    Sulli A; Ruaro B; Smith V; Paolino S; Pizzorni C; Pesce G; Cutolo M
    Arthritis Res Ther; 2017 Mar; 19(1):61. PubMed ID: 28320447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker.
    Hesselstrand R; Kassner A; Heinegård D; Saxne T
    Ann Rheum Dis; 2008 Sep; 67(9):1242-8. PubMed ID: 18065498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis.
    Yamaguchi Y; Ono J; Masuoka M; Ohta S; Izuhara K; Ikezawa Z; Aihara M; Takahashi K
    Br J Dermatol; 2013 Apr; 168(4):717-25. PubMed ID: 23110679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.